Last update Oct. 12, 2022

Clobenzorex Hydrochloride

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Psychostimulant precursor to amphetamine that is metabolized in the body to amphetamine (Cody 2002 and 2001) used as an anti-obesity medication. Oral administration once a day.

Since the last update we have not found any published data on its excretion in breast milk.

The paucity of published pharmacokinetic data does not allow prediction of its excretion in human milk, but its metabolite amphetamine is excreted in human milk (Cody 2001), with a T1/2 that would make it necessary to stop breastfeeding for about 100 hours after administration.

It can cause insomnia, anorexia, nervousness, and cardiomyopathy (Montastruc 2010, Cornaert 1986). Due to its negative risk-benefit balance, it has been withdrawn from the market by the main drug agencies (EMA and FDA) of most countries in the world.(Onakpoya 2016, AEMPS 2000)

There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)


See below the information of these related products:

  • Amfetamine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Dexamfetamine Sulfate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Hypocaloric Diet (Safe product and/or breastfeeding is the best option.)
  • Liraglutide (Safe product and/or breastfeeding is the best option.)
  • Maternal Sport (Safe product and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Naltrexone Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Orlistat (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Clobenzorex Hydrochloride is also known as


Clobenzorex Hydrochloride in other languages or writings:

Groups

Clobenzorex Hydrochloride belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Clobenzorex Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 296 daltons
Tmax 1 - 1.5 hours
T½ > 9 ? hours

References

  1. Jayasinghe S, Herath MP, Beckett JM, Ahuja KDK, Byrne NM, Hills AP. Exclusivity of breastfeeding and body composition: learnings from the Baby-bod study. Int Breastfeed J. 2021 May 19;16(1):41. Abstract Full text (link to original source)
  2. Schalla SC, Witcomb GL, Haycraft E. Body Shape and Weight Loss as Motivators for Breastfeeding Initiation and Continuation. Int J Environ Res Public Health. 2017 Jul 11;14(7). pii: E754. Abstract Full text (link to original source)
  3. López-Olmedo N, Hernández-Cordero S, Neufeld LM, García-Guerra A, Mejía-Rodríguez F, Méndez Gómez-Humarán I. The Associations of Maternal Weight Change with Breastfeeding, Diet and Physical Activity During the Postpartum Period. Matern Child Health J. 2016 Feb;20(2):270-80. Abstract
  4. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016 Nov 29;14(1):191. Review. Abstract Full text (link to original source)
  5. Jarlenski MP, Bennett WL, Bleich SN, Barry CL, Stuart EA. Effects of breastfeeding on postpartum weight loss among U.S. women. Prev Med. 2014 Dec;69:146-50. Abstract Full text (link to original source)
  6. Neville CE, McKinley MC, Holmes VA, Spence D, Woodside JV. The relationship between breastfeeding and postpartum weight change--a systematic review and critical evaluation. Int J Obes (Lond). 2014 Apr;38(4):577-90. Abstract
  7. Sámano R, Martínez-Rojano H, Godínez Martínez E, Sánchez Jiménez B, Villeda Rodríguez GP, Pérez Zamora J, Casanueva E. Effects of breastfeeding on weight loss and recovery of pregestational weight in adolescent and adult mothers. Food Nutr Bull. 2013 Jun;34(2):123-30. Abstract
  8. Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL; French Association of Regional PharmacoVigilance Centres.. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol. 2010 Mar;69(3):287-94. Abstract
  9. Hatsu IE, McDougald DM, Anderson AK. Effect of infant feeding on maternal body composition. Int Breastfeed J. 2008 Aug 6;3:18. Abstract Full text (link to original source)
  10. Dewey KG. Impact of breastfeeding on maternal nutritional status. Adv Exp Med Biol. 2004;554:91-100. Review. Abstract
  11. Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med. 2002 May;44(5):435-50. Review. Abstract
  12. Dewey KG, Cohen RJ, Brown KH, Rivera LL. Effects of exclusive breastfeeding for four versus six months on maternal nutritional status and infant motor development: results of two randomized trials in Honduras. J Nutr. 2001 Feb;131(2):262-7. Abstract Full text (link to original source) Full text (in our servers)
  13. Cody JT, Valtier S. Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex. J Anal Toxicol. 2001 Apr;25(3):158-65. Abstract
  14. AEMPS Retirada del mercado de los medicamentos anorexígenos de acción central. 2000 Full text (in our servers)
  15. Dewey KG, Heinig MJ, Nommsen LA. Maternal weight-loss patterns during prolonged lactation. Am J Clin Nutr. 1993 Aug;58(2):162-6. Abstract
  16. Kramer FM, Stunkard AJ, Marshall KA, McKinney S, Liebschutz J. Breast-feeding reduces maternal lower-body fat. J Am Diet Assoc. 1993 Apr;93(4):429-33. Abstract
  17. Cornaert P, Camblin J, Graux P, Anaye B, Dutoit A, Croccel L. [Congestive cardiomyopathy in addiction to clobenzorex, an anorexigenic drug]. Arch Mal Coeur Vaiss. 1986 Apr;79(4):515-8. French. Abstract

Total visits

19,888

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Amamanta of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM